Viking Therapeutics, Inc — Grafico, Quotazione e Notizie (NASDAQ:VKTX) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 4.1 B
Employee 53
Founded 2012
CEO Brian Lian
Website www.vikingtherapeutics.com
Headquarter Delaware, United States
FIGI BBG006LGV869
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

4.1 B Capitalizzazione di mercato

Notizie

Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing

NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

William Blair conferma il rating su Viking Therapeutic per i progressi clinici

Morgan Stanley conferma il rating su Viking Therapeutics per i progressi negli studi clinici

Viking Therapeutics completa l’arruolamento nello studio sul farmaco anti-obesità